A bicyclic peptide is a small chain of amino acids chemically linked to form two connected rings, like a paperclip bent into two loops. These double-ring structures make the molecule more stable and better at binding specific biological targets than many drugs, so they can act like precision keys for proteins that are hard to reach with traditional medicines. Investors watch developments in bicyclic peptides because they can lead to new, patentable therapies with distinct clinical and manufacturing risks and potential commercial upside.
xenograftmedical
A xenograft is biological tissue or cells taken from one species and placed into another, most commonly human tumor cells implanted into laboratory animals to study disease or test drugs. Investors watch xenograft results because they serve like a controlled dress rehearsal for a therapy: positive responses in these models can de‑risk programs, attract funding or partnerships, and influence the likelihood and timing of clinical trials and regulatory milestones.
head and neck squamous cell carcinomamedical
A type of cancer that starts in the thin, flat cells that line the mouth, throat, voice box and upper airway; imagine the lining like roof shingles that, when damaged, can grow into a harmful lump. It matters to investors because its diagnosis, treatment options and regulatory approvals drive demand for drugs, tests and therapies—affecting clinical trial outcomes, market size, company valuations and the financial risk/reward of healthcare investments.
muscle-invasive bladder cancermedical
A type of bladder cancer that has grown from the lining into the thick muscle layer of the bladder wall, making it more aggressive and likely to spread. For investors, this matters because muscle-invasive disease typically requires more intensive treatments, has different clinical trial endpoints and regulatory pathways, and represents a distinct market for drugs, surgeries and diagnostics — like a deeper-rooted problem needing heavier-duty tools.
EphA2medical
EPHA2 is a protein found on the surface of cells that acts like an antenna, receiving and sending signals that control how cells grow, move and stick together. Investors care because tumors and other diseases can hijack EPHA2, making it a common target for new drugs and diagnostics; progress or setbacks in therapies aimed at EPHA2 can materially affect the value and prospects of companies developing those treatments.
Nectin-4medical
A cell-surface protein that helps neighboring cells stick together and communicate; it is normally present during development but can become abundant on certain cancer cells. Investors pay attention because high levels make it a useful biomarker and a direct target for cancer therapies and diagnostic tests—similar to a distinctive flag on a building that lets a targeted treatment or test find and act on diseased tissue—affecting drug value, regulatory reviews, and market potential.
PET imagingmedical
PET imaging is a noninvasive medical scan that works like a molecular camera, using tiny radioactive tracers to reveal biological activity inside the body—for example metabolism, blood flow, or the presence of specific proteins. It matters to investors because PET results guide diagnosis, show whether a drug reaches its intended target and how patients respond, and therefore affect clinical trial success, regulatory approval, reimbursement decisions and demand for scanners, tracers and related services.
patient-derived xenograftmedical
A patient-derived xenograft (PDX) is a laboratory model created by implanting a tumor or diseased tissue taken directly from a human patient into an animal host that can support its growth. Because PDX models tend to mirror how a human tumor behaves and responds to treatments better than simple cell cultures, investors view their use as a stronger signal that preclinical drug results may translate to patients, lowering development risk much like a full-scale dress rehearsal raises confidence before opening night.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced an oral presentation and multiple poster presentations of five abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego.
Presentation Details:
Title: Preclinical assessment of BT5528 anti-tumor activity in cell-line-derived xenograft (CDX) models of head and neck squamous cell carcinoma (HNSCC)
Type: Oral Presentation
Session: Advanced Antibody, Conjugate, and Targeted Therapeutic Platforms
Date and Time: Sunday, April 19, 4:05-4:20 p.m. PT
Abstract Number: 1325
Lead Author: Lukas Stanczuk, Ph.D., Bicycle Therapeutics
Title: EphA2 expression across molecular and histological subtypes in muscle-invasive bladder cancer (MIBC) and its association with Nectin-4 and HER2
Type: Poster Presentation
Session: Clinical Research 1
Date and Time: Sunday, April 19, 2-5 p.m. PT
Abstract Number: LB012
Lead Author: Markus Eckstein, M.D., University Hospital Erlangen (FAU Erlangen -Nürnberg)
Title: An EphA2-targeting Bicycle Drug Conjugate (BDC), BT5528, in combination with nivolumab in patients (pts) with advanced solid tumors: results from a Phase 1/2 study
Type: Poster Presentation
Session: First-in-Human Phase I Clinical Trials
Date and Time: Monday, April 20, 9 a.m.-12 p.m. PT
Abstract Number: CT063
Lead Author: Babar Bashir, M.D., Thomas Jefferson University
Title: Preclinical assessment of BT5528 anti-tumor activity in patient-derived xenograft (PDX) models of pancreatic ductal adenocarcinoma (PDAC)
Type: Poster Presentation
Session: Hematologic Malignancies and Novel Therapeutic Modalities
Date and Time: Tuesday, April 21, 9 a.m.-12 p.m. PT
Abstract Number: 4518
Lead Author: Lukas Stanczuk, Ph.D., Bicycle Therapeutics
Title: Development and first clinical experiences of a phage display derived bicyclic peptide for EphA2-specific PET imaging
Type: Poster Presentation
Session: Diagnostic Biomarkers 2
Date and Time: Tuesday, April 21, 2-5 p.m. PT
Abstract Number: 6520
Lead Author: Ann-Christin Eder, Ph.D., University of Freiberg and German Cancer Consortium (DKTK)
The presentations will be made available in the Publications section of the Bicycle Therapeutics website at the beginning of the poster session.
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating nuzefatide pevedotin, formerly BT5528, a Bicycle® Drug Conjugate (BDC®) targeting EphA2, a historically undruggable target; a pipeline of other bicycle-based conjugate molecules, including Bicycle® Radioconjugates (BRC®) for radiopharmaceutical use; zelenectide pevedotin (formerly BT8009), a BDC® targeting Nectin-4, a well-validated tumor antigen; BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137; and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases in additional therapeutic areas.
Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, Mass. For more information, visit bicycletherapeutics.com.
